Literature DB >> 32632580

Surgical outcomes of second primary lung cancer after the extrapulmonary malignancy.

Kai-Hsiung Ko1, Hsu-Kai Huang2, Yi-I Chen2, Hung Chang2, Wu-Chuan Tsai3, Tsai-Wang Huang4.   

Abstract

OBJECTIVE: To study the surgical outcomes of patients with a second primary lung cancer after the extrapulmonary malignancy.
MATERIALS AND METHODS: Patients who underwent surgical resection for lung cancers between January 2005 and December 2014 were reviewed. Clinical data, imaging characteristics of tumors, surgical approaches, and outcomes were analyzed with a mean follow-up of 97 months.
RESULTS: Of 1075 patients, 166 (15.4%) had a second primary lung cancer after extrapulmonary malignancy. There were no differences in overall 5-year survival rates (81.8% for the group of lung cancer vs. 72.9% for the second primary lung cancer group, p = 0.069) and 5-year disease-free survival (70.1% for the lung cancer group vs. 70.3% for the second primary lung cancer group, p = 0.863) between the two groups. Gender, performance status, tumor size, and maximum standard uptake value (SUVmax) were significantly different between the two groups. After propensity-score matching analysis, patients in the group with lung cancers had better 5-year overall survival (88.1% vs. 72.1% for the group with second primary lung cancers, p = 0.016) and 5-year disease-free survival (80.6% vs. 70.3% for the group with second primary lung cancers; p = 0.054). In the second primary lung cancer group, the patients with preceding breast or thyroid cancers had better prognoses than did those with other extrapulmonary malignancy.
CONCLUSIONS: Second primary lung cancers following extrapulmonary malignancies were not uncommon. Surgical resection is considered for early stage secondary primary lung cancer after meticulous work up and result in fair outcome.

Entities:  

Keywords:  Prognosis; Second lung cancer; Surgery

Mesh:

Year:  2020        PMID: 32632580     DOI: 10.1007/s00432-020-03310-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  5 in total

1.  Development and validation of a competing risk model for second primary pancreatic ductal adenocarcinoma: A population-based study.

Authors:  Lishan Song; Chaojie Xu; Tong Zhang; Shengyang Chen; Zhigang Shi; Shuiquan Hu; Bingbing Cheng; Hao Tong; Guangkun Wei; Xiaoyong Li
Journal:  Front Surg       Date:  2022-08-30

2.  Second Primary Lung Adenocarcinoma After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma.

Authors:  Fen Xue; Xiaoshuang Niu; Chaosu Hu; Xiayun He
Journal:  Front Oncol       Date:  2022-02-24       Impact factor: 6.244

3.  Analysis of prognosis and treatment decisions for patients with second primary lung cancer following esophageal cancer.

Authors:  Jin-Luan Li; Hui Li; Qian Wu; Han Zhou; Yi Li; Yong-Heng Li; Jiancheng Li
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

4.  Radiomics Study for Discriminating Second Primary Lung Cancers From Pulmonary Metastases in Pulmonary Solid Lesions.

Authors:  Feiyang Zhong; Zhenxing Liu; Wenting An; Binchen Wang; Hanfei Zhang; Yumin Liu; Meiyan Liao
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

5.  Association of EGFR mutations in second primary lung cancer and HER2 expression in breast cancer survivors.

Authors:  Yoon Jung Jang; Seo Yun Kim; Hong Kyu Jung; Hye-Ryoun Kim; Cheol Hyeon Kim; Hyo-Rak Lee; Hye Jin Kang; Sung Hyun Yang; Hyesil Seol; Im Il Na
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.